Metformin treatment in the period after stroke prevents nitrative stress and restores angiogenic signaling in the brain in diabetes

Diabetes

Volumn 64, Issue 5, 2015, Pages 1804-1817

  Abdelsaid, Mohammed ^a,b   Prakash, Roshini ^c   Li, Weiguo ^a,b   Coucha, Maha ^b   Hafez, Sherif ^a,c   Johnson, Maribeth H ^d   Fagan, Susan C ^a,c   Ergul, Adviye ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d AUGUSTA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CASPASE 3; EPICATECHIN; GLUCOSE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXYNITRITE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TYROSINE; PROTEIN SUBUNIT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN ISCHEMIA; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPOGLYCEMIA; NITRATION; NITRATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; REOXYGENATION; REPERFUSION INJURY; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; PROTEIN SUBUNIT; SIGNAL TRANSDUCTION; VASCULARIZATION; WISTAR RAT;

ANIMALS; APOPTOSIS; BRAIN; DIABETES MELLITUS; METFORMIN; NEOVASCULARIZATION, PHYSIOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; STROKE; TYROSINE;

EID: 84981508397     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1423     Document Type: Article

References (49)

1. Ergul A, Alhusban A, Fagan SC. Angiogenesis: A harmonized target for recovery after stroke. Stroke 2012;43:2270-2274.
2. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010;68(Suppl. 2):S74-S87.
3. Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs 2013;13:57-69.
4. Ergul A, Li W, Elgebaly MM, Bruno A, Fagan SC. Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature. Vascul Pharmacol 2009;51:44-49.
5. Prakash R, Somanath PR, El-Remessy AB, et al. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes 2012;61:1533-1542.
6. Prakash R, Li W, Qu Z, Johnson MA, Fagan SC, Ergul A. Vascularization pattern after ischemic stroke is different in control versus diabetic rats: Relevance to stroke recovery. Stroke 2013;44:2875-2882.
7. Prakash R, Johnson M, Fagan SC, Ergul A. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. PLoS One 2013; 8:e56264.
8. Ergul A, Elgebaly MM, Middlemore ML, et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol 2007;7:33.
9. Kozak A, Ergul A, El-Remessy AB, et al. Candesartan augments ischemiainduced proangiogenic state and results in sustained improvement after stroke. Stroke 2009;40:1870-1876.
10. Elgebaly MM, Prakash R, Li W, et al. Vascular protection in diabetic stroke: Role of matrix metalloprotease-dependent vascular remodeling. J Cereb Blood Flow Metab 2010;30:1928-1938.
11. Ergul A, Abdelsaid M, Fouda AY, Fagan SC. Cerebral neovascularization in diabetes: implications for stroke recovery and beyond. J Cereb Blood Flow Metab 2014;34:553-563.
12. Yun J, Rocic P, Pung YF, et al. Redox-dependent mechanisms in coronary collateral growth: The "redox window" hypothesis. Antioxid Redox Signal 2009; 11:1961-1974.
13. Kelly-Cobbs AI, Prakash R, Li W, et al. Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes. Am J Physiol Heart Circ Physiol 2013;304:H806-H815.
14. Abdelsaid MA, Pillai BA, Matragoon S, Prakash R, Al-Shabrawey M, El-Remessy AB. Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther 2010;332:125-134.
15. Abdelsaid MA, El-Remessy AB. S-glutathionylation of LMW-PTP regulates VEGF-mediated FAK activation and endothelial cell migration. J Cell Sci 2012; 125:4751-4760.
16. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 2012;12:148-158.
17. Ding Q, Ying Z, Gómez-Pinilla F. Exercise influences hippocampal plasticity by modulating brain-derived neurotrophic factor processing. Neuroscience 2011; 192:773-780.
18. Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O. Longterm neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke 2007;38:3032- 3039.
19. Ye Y, Wang G, Wang H, Wang X. Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neurosci Lett 2011;503:15-19.
20. Zhu M, Bi X, Jia Q, Shangguan S. The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor. Biomed Pharmacother 2010;64:208-213.
21. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999;274:16349-16354.
22. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 39- kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
23. Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 2013;92:1037-1045.
24. Boodhwani M, Sellke FW. Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress. Antioxid Redox Signal 2009;11: 1945-1959.
25. Chen J, Ye X, Yan T, et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats. Stroke 2011;42:3551-3558.
26. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci U S A 2004;101:4003-4008.
27. Gürsoy-Ozdemir Y, Can A, Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 2004; 35:1449-1453.
28. Tan S, Bose R, Derrick M. Hypoxia-ischemia in fetal rabbit brain increases reactive nitrogen species production: quantitative estimation of nitrotyrosine. Free Radic Biol Med 2001;30:1045-1051.
29. Gürsoy-Ozdemir Y, Bolay H, Saribas O, Dalkara T. Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 2000;31:1974-1980; discussion 1981.
30. Bailey DM, Taudorf S, Berg RM, et al. Increased cerebral output of free radicals during hypoxia: implications for acute mountain sickness? Am J Physiol Regul Integr Comp Physiol 2009;297:R1283-R1292.
31. Sirinyan M, Sennlaub F, Dorfman A, et al. Hyperoxic exposure leads to nitrative stress and ensuing microvascular degeneration and diminished brain mass and function in the immature subject. Stroke 2006;37:2807-2815.
32. Sun L, Yang L, Fu Y, et al. Capacity of HSYA to inhibit nitrotyrosine formation induced by focal ischemic brain injury. Nitric Oxide 2013;35:144-151.
33. Coucha M, Li W, Johnson MH, Fagan SC, Ergul A. Protein nitration impairs the myogenic tone of rat middle cerebral arteries in both ischemic and nonischemic hemispheres after ischemic stroke. Am J Physiol Heart Circ Physiol 2013;305:H1726-H1735.
34. Hall ED. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011;8:152-167.
35. Hall ED, Wang JA, Miller DM. Relationship of nitric oxide synthase induction to peroxynitrite-mediated oxidative damage during the first week after experimental traumatic brain injury. Exp Neurol 2012;238:176-182.
36. Wang XL, Rainwater DL, Leone A, Mahaney MC. Effects of diabetes on plasma nitrotyrosine levels. Diabet Med 2004;21:577-580.
37. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168:235-244.
38. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003;162:1995-2004.
39. Chao XD, Ma YH, Luo P, et al. Up-regulation of heme oxygenase-1 attenuates brain damage after cerebral ischemia via simultaneous inhibition of superoxide production and preservation of NO bioavailability. Exp Neurol 2013; 239:163-169.
40. El-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 2005;118:243-252.
41. Hellberg CB, Boggs SE, Lapetina EG. Phosphatidylinositol 3-kinase is a target for protein tyrosine nitration. Biochem Biophys Res Commun 1998;252: 313-317.
42. Abdelsaid M, Kaczmarek J, Coucha M, Ergul A. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: Relevance to glycemic control. Life Sci 18 January 2014 [Epub ahead of print].
43. Abdelsaid M, Ma H, Coucha M, Ergul A. Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes. Life Sci 2014;118:263-267.
44. Duckworth WC. Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 2001;3:383-391.
45. Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158:631-641.
46. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.
47. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
48. Schernthaner G. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010;160:8-19.
49. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937-942.